Item 5. Other Information
Item 5. OTHER INFORMATION
Rule 10b5-1 Trading Plans
The following table shows the “Rule 10b5-1 trading arrangements” and “non-Rule 10b5-1 trading arrangements” (as each term is defined in Item 408(a) of Regulation S-K) adopted or terminated by our directors and executive officers during the quarter ended June 30, 2023:
Trading Arrangement
Name and Position Action Date Rule 10b5-1* Non-Rule
10b5-1** Total Number of
Shares to be Sold Expiration Date
Gary Pace
Director
Adopt 6/16/2023 X 8,000 6/3/2024
Gary Pace
Director
Terminate (1)
5/11/2023 X 7,000 5/11/2023
* Intended to satisfy the affirmative defense of Rule 10b5-1(c).
** Not intended to satisfy the affirmative defense of Rule 10b5-1(c).
(1) Trading arrangement was originally adopted on June 13, 2022 .
Pacira BioSciences, Inc. | Q2 2023 Form 10-Q | Page 47
Table of Contents
Item 6. EXHIBITS
The exhibits listed below are filed or furnished as part of this report.
Exhibit Number Description
10.1
Amended and Restated 2011 Stock Incentive Plan.(1)†
10.2
Side Letter dated June 5, 2023, to the Manufacturing and Supply Agreement by and between the Registrant and Patheon UK Limited.††
31.1
Certification of Chief Executive Officer and Chairman pursuant to Rule 13a-14(a) and 15d-14(a), as amended.*
31.2
Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and 15d-14(a), as amended.*
32.1
Certification of Chief Executive Officer and Chairman and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**
101 The following materials from the Quarterly Report on Form 10-Q of Pacira BioSciences, Inc. for the quarter ended June 30, 2023, formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) the Condensed Consolidated Balance Sheets; (ii) the Condensed Consolidated Statements of Operations; (iii) the Condensed Consolidated Statements of Comprehensive Income; (iv) the Condensed Consolidated Statements of Stockholders’ Equity; (v) the Condensed Consolidated Statements of Cash Flows; and (vi) the Condensed Notes to Consolidated Financial Statements.*
104 Cover Page Interactive Data File (Formatted as Inline XBRL and contained in Exhibit 101).
* Filed herewith.
** Furnished herewith.
† Denotes management contract or compensatory plan or arrangement.
†† Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) of Regulation S-K. The omitted information is (i) not material and (ii) would cause competitive harm to the Company if publicly disclosed.
(1) Incorporated by reference to the Registrant’s Current Report on Form 8-K, filed on June 20, 2023.
Pacira BioSciences, Inc. | Q2 2023 Form 10-Q | Page 48
Table of Contents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
PACIRA BIOSCIENCES, INC.
(REGISTRANT)
Date: August 2, 2023 By: /s/ DAVID STACK
David Stack
Chief Executive Officer and Chairman
(Principal Executive Officer)
Date: August 2, 2023 By: /s/ CHARLES A. REINHART, III
Charles A. Reinhart, III
Chief Financial Officer
(Principal Financial Officer)
Pacira BioSciences, Inc. | Q2 2023 Form 10-Q | Page 49
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.